| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| BUY | BUY | BUY | BUY | NEUTRAL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 3.70▲ | 3.70▲ | 3.69▲ | 3.71▲ | 3.49▲ |
| MA10 | 3.67▲ | 3.69▲ | 3.69▲ | 3.56▲ | 3.59▲ |
| MA20 | 3.70▲ | 3.70▲ | 3.69▲ | 3.45▲ | 3.55▲ |
| MA50 | 3.63▲ | 3.55▲ | 3.52▲ | 3.56▲ | 4.23▼ |
| MA100 | 3.47▲ | 3.42▲ | 3.46▲ | 3.60▲ | 5.18▼ |
| MA200 | 3.47▲ | 3.51▲ | 3.57▲ | 4.20▼ | 6.81▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.002▼ | -0.008▼ | -0.008▼ | 0.053▲ | 0.054▲ |
| RSI | 57.233▲ | 60.618▲ | 62.128▲ | 58.784▲ | 49.006▼ |
| STOCH | 56.540 | 41.667 | 37.778 | 87.864▲ | 36.248 |
| WILL %R | -26.667 | -26.667 | -35.294 | -9.722▲ | -41.912 |
| CCI | 66.722 | 72.582 | 56.732 | 103.805▲ | 67.211 |
|
Tuesday, January 19, 2021 03:08 PM
© 2021 Insider Inc. and finanzen.net GmbH (Imprint). All rights reserved. Registration on or use of this site constitutes acceptance of our Terms of Service and ...
|
|
Tuesday, January 19, 2021 05:09 AM
TEL AVIV, Israel, Jan. 19, 2021 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for ...
|
|
Tuesday, January 19, 2021 05:00 AM
Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory diseases, announced today that it will host a Key Opinion Leader symposium and pipeline ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 22/01/21 | 3.745 | 3.79 | 3.57 | 3.75 | 87,600 |
| 21/01/21 | 3.75 | 3.78 | 3.645 | 3.67 | 86,100 |
| 20/01/21 | 3.80 | 3.82 | 3.65 | 3.78 | 139,700 |
| 19/01/21 | 3.789 | 3.81 | 3.611 | 3.75 | 341,500 |
| 15/01/21 | 3.48 | 3.62 | 3.36 | 3.59 | 167,100 |
| 14/01/21 | 3.40 | 3.499 | 3.385 | 3.48 | 115,300 |
| 13/01/21 | 3.499 | 3.499 | 3.36 | 3.37 | 66,000 |
| 12/01/21 | 3.37 | 3.474 | 3.33 | 3.38 | 83,800 |
| 11/01/21 | 3.47 | 3.47 | 3.355 | 3.40 | 92,988 |
| 08/01/21 | 3.39 | 3.476 | 3.35 | 3.42 | 90,200 |
|
|
||||
|
|
||||
|
|